Extracellular vesicle-bound VEGF in oral squamous cell carcinoma and its role in resistance to Bevacizumab Therapy
Antagonists targeting HSPG might potentially overcome the resistance of EV-VEGF to bevacizumab and serve as an alternative for anti-VEGF therapy in OSCC.
Authors
- Tingjiao Liu (ORCID: https://orcid.org/0000-0001-5850-789X)
- Xue Liu (ORCID: https://orcid.org/0000-0003-1133-9475)
- Jiao Li (ORCID: https://orcid.org/0000-0002-8027-5877)
- Weidong Niu (ORCID: https://orcid.org/0000-0001-8659-7650)
- Jiasheng Zhou
- Qi Dong
Institutions
- Dalian Medical University (CN)
- Fudan University (CN)
- Shanghai Stomatological Hospital (CN)
Publication Details
- Journal
- Cancer Cell International
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1186/s12935-024-03476-1
- Citations
- 8
- Primary Topic
- Extracellular vesicles in disease
- Type
- article
- Field-Weighted Citation Impact
- 1.87
Funders
- Natural Science Foundation of Shanghai
- National Natural Science Foundation of China